263 related articles for article (PubMed ID: 14581375)
1. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
[TBL] [Abstract][Full Text] [Related]
2. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
Mackey JR; Yao SY; Smith KM; Karpinski E; Baldwin SA; Cass CE; Young JD
J Natl Cancer Inst; 1999 Nov; 91(21):1876-81. PubMed ID: 10547395
[TBL] [Abstract][Full Text] [Related]
4. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Damaraju VL; Scriver T; Mowles D; Kuzma M; Ryan AJ; Cass CE; Sawyer MB
Clin Cancer Res; 2014 Jan; 20(1):176-86. PubMed ID: 24170548
[TBL] [Abstract][Full Text] [Related]
6. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
7. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
[TBL] [Abstract][Full Text] [Related]
9. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
10. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
11. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
[TBL] [Abstract][Full Text] [Related]
12. Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
Damaraju VL; Smith KM; Mowles D; Nowak I; Karpinski E; Young JD; Robins MJ; Cass CE
Biochem Pharmacol; 2011 Jan; 81(1):82-90. PubMed ID: 20854794
[TBL] [Abstract][Full Text] [Related]
13. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
Bhutia YD; Hung SW; Patel B; Lovin D; Govindarajan R
Cancer Res; 2011 Mar; 71(5):1825-35. PubMed ID: 21343396
[TBL] [Abstract][Full Text] [Related]
14. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.
Mackey JR; Mani RS; Selner M; Mowles D; Young JD; Belt JA; Crawford CR; Cass CE
Cancer Res; 1998 Oct; 58(19):4349-57. PubMed ID: 9766663
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
16. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
17. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.
Marcé S; Molina-Arcas M; Villamor N; Casado FJ; Campo E; Pastor-Anglada M; Colomer D
Haematologica; 2006 Jul; 91(7):895-902. PubMed ID: 16818276
[TBL] [Abstract][Full Text] [Related]
18. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
19. Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells.
Burke T; Lee S; Ferguson PJ; Hammond JR
J Pharmacol Exp Ther; 1998 Sep; 286(3):1333-40. PubMed ID: 9732397
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
